(BQ) Part 1 book "Molecular histopathology and tissue biomarkers in drug and diagnostic development" presentation of content: Histopathology - A canvas and landscape of disease in drug and diagnostic development, histopathology in mouse models of rheumatoid arthritis, markers used for visualization and quantification of blood and lymphatic vessels, image analysis tools for quantification of spinal motor neuron subtype identities,. | Methods in Pharmacology and Toxicology Steven J. Potts David A. Eberhard Keith A. Wharton, Jr. Editors Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development METHODS AND IN PHARMACOLOGY TOXICOLOGY Series Editor Y. James Kang Department of Medicine University of Louisville School of Medicine Prospect, Kentucky, USA For further volumes: Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development Edited by Steven J. Potts Flagship Biosciences, LLC, Westminster, CO, USA David A. Eberhard University of North Carolina, Chapel Hill, NC, USA Keith A. Wharton, Jr. Novartis Institutes for BioMedical Research, Cambridge, MA, USA Editors Steven J. Potts Flagship Biosciences, LLC Westminster, CO, USA David A. Eberhard University of North Carolina Chapel Hill, NC, USA Keith A. Wharton, Jr. Novartis Institutes for BioMedical Research Cambridge, MA, USA ISSN 1557-2153 ISSN 1940-6053 (electronic) Methods in Pharmacology and Toxicology ISBN 978-1-4939-2680-0 ISBN 978-1-4939-2681-7 (eBook) DOI /978-1-4939-2681-7 Library of Congress Control Number: 2015939268 Springer New York Heidelberg Dordrecht London # Springer Science+Business Media New York 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general
